What do systematic reviews say?

Adverse events · adult patients with haematological malignancies

Adverse events · cancer patients receiving myelotoxic chemotherapy

Adverse events · participants with haematological malignancies

Severe adverse events · newly diagnosed patients with myelodysplastic syndromes

Serious adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Serious adverse events · individuals with moderate to severe disease

Serious adverse events · newly diagnosed, transplant‐ineligible adults with symptomatic multiple myeloma

Serious adverse events · patients with primary CNS lymphoma

Grades 3 and 4 adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

Grades 3 and 4 adverse events · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

Adverse events ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)

All adverse events – not reported · people with chronic lymphocytic leukaemia

Serious adverse events ‐ not reported · individuals with moderate to severe disease

Serious adverse events ‐ not reported · outpatients withmild disease